|
Market Closed -
Sao Paulo
14:20:22 23/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 66.08 BRL | -0.06% |
|
+0.41% | +15.26% |
| 12:05am | AstraZeneca Readies New Portfolio of Targeted Cancer Therapies | DJ |
| 10-23 | Calendar Monday, October 26 - Friday, October 30 | FW |
Company Valuation: Gilead Sciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 91,081 | 107,677 | 100,942 | 115,118 | 152,281 | 193,483 | - | - |
| Change | - | 18.22% | -6.25% | 14.04% | 32.28% | 27.06% | - | - |
| Enterprise Value (EV) 1 | 118,530 | 126,522 | 118,665 | 131,838 | 169,585 | 214,755 | 207,102 | 200,065 |
| Change | - | 6.74% | -6.21% | 11.1% | 28.63% | 26.64% | -3.56% | -3.4% |
| P/E | 14.7x | 23.6x | 18x | 243x | 18.1x | -45.5x | 19.3x | 17.7x |
| PBR | 4.32x | 5.05x | 4.48x | 5.98x | 6.73x | 13.6x | 9.63x | 7.33x |
| PEG | - | -0.9x | 0.8x | -2.7x | 0x | 0x | -0x | 2x |
| Capitalization / Revenue | 3.34x | 3.95x | 3.72x | 4x | 5.17x | 6.29x | 5.88x | 5.59x |
| EV / Revenue | 4.34x | 4.64x | 4.38x | 4.59x | 5.76x | 6.98x | 6.29x | 5.78x |
| EV / EBITDA | 8.12x | 8.86x | 9.01x | 11.7x | 10.6x | 27.1x | 11.3x | 10.6x |
| EV / EBIT | 9.45x | 10.4x | 11.3x | 15.5x | 12.9x | 65.9x | 12.9x | 11.7x |
| EV / FCF | 11x | 15.2x | 16x | 12.8x | 17.9x | -408x | 14.4x | 14.4x |
| FCF Yield | 9.12% | 6.59% | 6.25% | 7.82% | 5.58% | -0.25% | 6.95% | 6.93% |
| Dividend per Share 2 | 2.84 | 2.92 | 3 | 3.08 | 3.16 | 3.297 | 3.358 | 3.077 |
| Rate of return | 3.91% | 3.4% | 3.7% | 3.33% | 2.57% | 2.11% | 2.15% | 1.97% |
| EPS 2 | 4.93 | 3.64 | 4.5 | 0.38 | 6.78 | -3.431 | 8.089 | 8.804 |
| Distribution rate | 57.6% | 80.2% | 66.7% | 811% | 46.6% | -96.1% | 41.5% | 34.9% |
| Net sales 1 | 27,305 | 27,281 | 27,116 | 28,754 | 29,443 | 30,784 | 32,905 | 34,595 |
| EBITDA 1 | 14,598 | 14,283 | 13,177 | 11,287 | 15,953 | 7,938 | 18,367 | 18,821 |
| EBIT 1 | 12,548 | 12,180 | 10,484 | 8,520 | 13,193 | 3,261 | 16,047 | 17,112 |
| Net income 1 | 6,225 | 4,592 | 5,665 | 480 | 8,510 | -4,375 | 10,282 | 10,920 |
| Net Debt 1 | 27,449 | 18,845 | 17,723 | 16,720 | 17,304 | 21,272 | 13,619 | 6,583 |
| Reference price 2 | 72.61 | 85.85 | 81.01 | 92.37 | 122.74 | 156.04 | 156.04 | 156.04 |
| Nbr of stocks (in thousands) | 1,254,384 | 1,254,244 | 1,246,042 | 1,246,266 | 1,240,680 | 1,239,955 | - | - |
| Announcement Date | 01/02/22 | 02/02/23 | 06/02/24 | 11/02/25 | 10/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 37.06x | 13.1x | 27.8x | 0.54% | 1,135B | |
| 38.61x | 6.49x | 18.27x | 2.02% | 635B | |
| 36.46x | 8.38x | 17.29x | 2.41% | 505B | |
| 20.87x | 5.11x | 12.73x | 2.56% | 378B | |
| 105.89x | 5.92x | 25.41x | 2.34% | 358B | |
| 21.76x | 5.68x | 13.94x | 2.81% | 295B | |
| 22.43x | 4.53x | 12.94x | 1.95% | 266B | |
| 27.87x | 7.16x | 12.81x | 2.3% | 237B | |
| -45.48x | 6.98x | 27.06x | 2.11% | 193B | |
| Average | 29.50x | 7.04x | 18.69x | 2.12% | 444.85B | |
| Weighted average by Cap. | 35.23x | 8.29x | 20.39x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GILD Stock
- GILD34 Stock
- Valuation Gilead Sciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
